期刊
CANCER RESEARCH AND TREATMENT
卷 54, 期 4, 页码 1240-1255出版社
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2021.1194
关键词
Fibromatosis aggressive; Imatinib mesylate; Clinical trial phase II; Computational biology; Whole-genome sequencing; Transcriptome
类别
This study investigates the potential roles of NOTCH2 and HES1 in the clinical response to imatinib in patients with desmoid tumor. The results suggest a significant correlation between NOTCH2 mutations and clinical response to imatinib, and HES1 expression can differentiate responders from non-responders.
Purpose Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/beta-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe potential roles of NOTCH2 and HES1 in clinical response to imatinib at genome and transcriptome levels. Materials and Methods We identified somatic mutations in coding and noncoding regions via whole-genome sequencing. To validate the genetic interaction with expression level in desmoid-tumor condition, we utilized large-scale whole-genome sequencing and transcriptome datasets from the Pan-Cancer Analysis of Whole Genomes project. RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response. Results Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for = 1 year. With gene-wise functional analyses, we detected a significant correlation between recurrent NOTCH2 noncoding mutations and clinical response to imatinib. Based on Pan-Cancer Analysis of Whole Genomes data analyses, NOTCH2 mutations affect expression levels particularly in the presence of CTNNB1 missense mutations. By analyzing RNA-sequencing with additional desmoid tumor samples, we found that NOTCH2 expression was significantly correlated with HES1 expression. Interestingly, NOTCH2 had no statistical power to discriminate between responders and non-responders. Instead, HES1 was differentially expressed with statistical significance between responders and non-responders. Conclusion Imatinib was effective and well tolerated for advanced desmoid tumor treatment. Our results show that HES1, regulated by NOTCH2, as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据